Latest news with #PRTA
Yahoo
28-07-2025
- Business
- Yahoo
Prothena to Report Second Quarter 2025 Financial Results on August 4
DUBLIN, July 28, 2025--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its second quarter and first six months of 2025 financial results on Monday, August 4, 2025, after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with the financial results release on August 4. About Prothena Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena's pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Parkinson's disease and a number of other neurodegenerative diseases. For more information, please visit the Company's website at and follow the Company on X (formerly Twitter) @ProthenaCorp. View source version on Contacts Mark Johnson, CFA, Vice President, Investor Relations650-417-1974,
Yahoo
29-05-2025
- Business
- Yahoo
Citizens JMP Slashes Prothena (PRTA) to $29 from $78 After AFFIRM-AL Trial Fails
On May 27, Citizens JMP lowered the firm's price target on Prothena Corporation plc (NASDAQ:PRTA) to $29 from $78 but kept an Outperform rating on the shares. The notable price target decrease came after Prothena Corporation plc (NASDAQ:PRTA) announced negative results from the Phase 3 AFFIRM-AL trial for birtamimab in AL amyloidosis on May 23. The trial missed the primary and secondary endpoints, which is why the company plans to discontinue it. A biopharmaceutical facility with technicians working on a manufacturing line of treatments and preventions. The analyst told investors in a research note that substantial cost-reducing initiatives are expected to follow the discontinuation of the AFFIRM-AL trial, including a considerable workforce reduction. Citizens JMP also announced plans to remove birtamimab from its model. However, the firm is bullish on Prothena Corporation plc (NASDAQ:PRTA), primarily due to the potential success of PRX012, its anti-Abeta immunotherapy for Alzheimer's disease. Prothena Corporation (NASDAQ:PRTA) is a clinical-stage neuroscience company that discovers and develops novel therapies for serious diseases. Its clinical pipeline includes both partnered and wholly owned therapies for AL amyloidosis, Alzheimer's disease, ATTR amyloidosis, Parkinson's disease, and other neurodegenerative diseases. While we acknowledge the potential of PRTA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PRTA and that has 100x upside potential, check out our report about the . READ NEXT: and . Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
28-05-2025
- Business
- Yahoo
Oppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from Outperform
Oppenheimer downgraded Prothena Corporation plc (NASDAQ:PRTA) to Perform from Outperform on May 27 without a price target. This rating update came after Prothena Corporation's (NASDAQ:PRTA) May 23 announcement that its Phase 3 AFFIRM-AL trial for birtamimab in amyloid light chain amyloidosis failed to meet the primary endpoint of all-cause mortality. A doctor examining the results of a patient's medical scan displayed on a computer monitor. The analyst told investors in a research note that with a hazard ratio of 0.915, there was essentially an overlap between the survival curve for birtamimab and the control arm. Failing to meet primary and secondary endpoints, Prothena Corporation (NASDAQ:PRTA) is discontinuing the trial. Despite these negative results, Oppenheimer remains optimistic about the company's prospects, primarily due to its various partnered and internal programs. However, the firm did comment that the AFFIRM-AL catalyst was the key driver of its bullish thesis. Prothena Corporation (NASDAQ:PRTA) is a clinical-stage neuroscience company that discovers and develops novel therapies for serious diseases. Its clinical pipeline includes both partnered and wholly owned therapies for AL amyloidosis, Alzheimer's disease, ATTR amyloidosis, Parkinson's disease, and other neurodegenerative diseases. While we acknowledge the potential of PRTA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PRTA and that has 100x upside potential, check out our report about the . READ NEXT: and . Disclosure: None.
Business Insider
24-05-2025
- Business
- Business Insider
Prothena announces AFFIRM-AL trial did not meet primary endpoint
Prothena (PRTA) announced the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis did not meet its primary endpoint. Based on these results, the company will discontinue the development of birtamimab, including stopping the open label extension of the AFFIRM-AL clinical trial. In the Phase 3 AFFIRM-AL clinical trial, the primary endpoint of time to all-cause mortality was not met for patients treated with birtamimab. In addition, neither of the secondary endpoints were met: 6-minute walk test distance and Short Form-36 version 2 Physical Component Score. Birtamimab was generally safe and well-tolerated, consistent with its established safety profile. In June, the company expects to provide details of plans to reduce ongoing operating expenses. The results of the company's review of its business options will be communicated as appropriate once the analysis and plans are finalized. Confident Investing Starts Here:
San Francisco Chronicle
08-05-2025
- Business
- San Francisco Chronicle
Prothena: Q1 Earnings Snapshot
DUBLIN (AP) — DUBLIN (AP) — Prothena Corp. (PRTA) on Thursday reported a loss of $60.2 million in its first quarter. The Dublin-based company said it had a loss of $1.12 per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 92 cents per share. The drug developer posted revenue of $2.8 million in the period. _____
